Zimmer Biomet Hlds

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. The company operates through the following segments: Americas Orthopedics, EMEA, Asia Pacific, and Americas Spine and Global Dental. The Americas Orthopedics segment consists of the U.S. market and includes other North, Central, and South American markets for the firm’s orthopedic product categories. The EMEA segment focuses on Europe and includes the Middle East and African markets for all product categories except Dental. The Asia Pacific segment consists of Japan, China, and Australia and includes other Asian and Pacific markets for all product categories except Dental. The Americas Spine and Global Dental segment focuses on the U.S. market and includes other North, Central, and South American markets for the firm's spine business, and all geographic markets for its dental business. This segment is also involved in research, development engineering, medical education, and brand management. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zimmer Biomet posts solid Q4 growth amidst supply chain challenges

Zimmer Biomet reported strong Q4 performance with growth in key segments, while acknowledging challenges in the operating environment. The company is focused on innovation, margin expansion, and driving earnings growth for sustainable future success.

Zimmer Biomet excels in Q1, raises outlook and eyes M&A

Zimmer Biomet's exceptional Q1 performance led to a significant raise in full-year outlook.
The company is well-positioned to capitalize on growth opportunities with new product launches.
Despite challenges in the supply chain and pricing pressure, Zimmer Biomet remains resilient.
Strategic focus on innovation and potential M&A activities to drive future growth.

Zimmer Biomet surpasses Q2 expectations, eyes China growth and margin expansion

Zimmer Biomet's Q2 performance exceeded expectations with strong sales and adjusted EPS.
Challenges persist in managing supply constraints and backlog issues.
Opportunities lie in expanding into the China market, new product launches, and margin improvement strategies.
Overall, Zimmer Biomet remains optimistic about growth despite supply challenges in the near term.

Zimmer Biomet posts solid Q3 results, eyes sustainable growth

Zimmer Biomet's Q3 performance reflects growth in key segments and reaffirmed guidance for 2023, showcasing operational effectiveness and strategic focus.
The company's commitment to innovation, sustainable growth, and margin expansion post-2024 positions it well for future success despite challenges in certain markets.
Opportunities in accelerating growth through innovation, strategic acquisitions, and margin expansion present avenues for long-term value creation and sustained performance.

Zimmer Biomet reports strong Q4 earnings, eyes sustainable growth

Zimmer Biomet had a strong Q4 2023, with revenue and EPS growth despite challenges, and aims to outpace market growth in 2024 through strategic imperatives.
The company's focus on operational excellence, innovation, and diversification, along with cost-saving initiatives, supports its outlook for sustainable growth.
While facing challenges like supply issues and margin pressures, Zimmer Biomet remains confident in its ability to drive revenue growth and expand operating margins.
Opportunities in new product launches, efficiency initiatives, and market dynamics position Zimmer Biomet for continued success and earnings growth in 2024 and beyond.

Zimmer Biomet surpasses Q1 expectations, eyes growth through innovation

Zimmer Biomet delivered strong Q1 results, showcasing revenue growth, improved margins, and successful product launches. While facing challenges in sustaining ROSA segment growth, the company remains optimistic about expanding market share and driving innovation through strategic initiatives.

Zimmer Biomet posts solid Q2 results, eyes growth opportunities ahead

Zimmer Biomet's Q2 performance reflects resilience and strategic progress, with a focus on market share, financial targets, and operational efficiency. The company is poised for growth in international markets and anticipates a stronger second half with improved cash flow.

Zimmer Biomet reports solid Q3 performance amidst ERP challenges

Zimmer Biomet delivered a strong Q3 performance with sales growth and improved margins. Despite ERP challenges, the company remains focused on innovation, operational excellence, and growth strategies. Updated 2024 guidance reflects confidence in sustained revenue growth and margin improvement.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zimmer Biomet Holdings, Inc. engages in the design, manufacture, and marketing of orthopedic reconstructive products. The firm also offers sports medicine, biologics, extremities, and trauma products, spine, craniomaxillofacial, and thoracic products, office-based technologies, dental implants, and related surgical products. It operates through the following geographical segments: Americas, Europe Middle East and Africa, and Asia Pacific. The Americas segment consists of the U.S. and includes other North, Central and South American markets. The Europe Middle East and Africa segment includes France, Germany, Italy, Spain, and the United Kingdom. The Asia Pacific segment refers to the key markets such as Japan, China, Australia, New Zealand, Korea, Taiwan, India, Thailand, Singapore, Hong Kong, and Malaysia. The company was founded by Justin O. Zimmer in 1927 and is headquartered in Warsaw, IN.

Zimmer Biomet (ZBH) is expected to have gained from the uptake of Persona OsseoTi Keel Tibia for Cementless Knee Replacement in the fourth quarter.

What's in Store for Zimmer Biomet (ZBH) in Q4 Earnings?

Zimmer Biomet is focusing on growth acceleration after spinning off divisions and refocusing on high-growth areas in the medical device market. The company's growth target is supported by investments in R&D for new product launches and strategic targeting of high-growth markets. Zimmer's ROSA system holds promise for accelerating growth in the Total Knee segment and tapping into an underpenetrated market with substantial growth potential.

Zimmer Biomet: Growth Acceleration Is Likely Driven By ROSA; Initiate With 'Buy'

WARSAW, Ind. , Jan. 16, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its fourth quarter earnings conference call will be webcast on Thursday, February 8, 2024 at 8:30 a.m.

Zimmer Biomet Announces Webcast and Conference Call of Fourth Quarter 2023 Financial Results

WARSAW, Ind. , Jan. 5, 2024 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that Louis A.

Zimmer Biomet Announces Appointment of Louis A. Shapiro to Board of Directors

International Flavors & Fragrances

Shopify

Companies with unique competitive advantages aren't always rewarded by the market: Etsy Inc. NASADQ: ETSY, International Flavors & Fragrances Inc. NYSE: IFF and Zimmer Biomet Holdings Inc. NYSE: ZBH are examples of stocks that appear to be trading well below their intrinsic value, based on earnings projections.

Hidden gems: 3 undervalued stocks with a unique competitive edge

Abbott Labs

BellRing Brands Inc

Hershey

WK Kellogg Co

Mondelez

Medtronic

Insulet

Post Holdings

J. M. Smucker

Stryker

Utz Brands

Investors have such high hopes for popular weight-loss medications like Wegovy and Ozempic, the wonder drugs have sent shock waves through the stock market.

Ozempic and other weight-loss drugs' popularity set these stocks up for big gains

Zimmer Biomet's (ZBH) focus on emerging markets raises optimism about the stock.

3 Reasons to Hold Zimmer Biomet (ZBH) Stock in Your Portfolio

WARSAW, Ind. , Dec. 19, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 42nd Annual J.P.

Zimmer Biomet to Present at the 42nd Annual J.P. Morgan Healthcare Conference

ZBH reported strong 3Q23 performance and has provided a positive business outlook. The company's new innovations and increasing presence in ambulatory surgery centers (ASCs) are driving growth. GLP-1 should be a tailwind for ZBH, extending its long-term growth runway.

Zimmer Biomet Holdings: Visible Growth Drivers And Strong Execution

WARSAW, Ind. , Dec. 14, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the fourth quarter of 2023.

Zimmer Biomet Announces Quarterly Dividend for Fourth Quarter of 2023

Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?

Why Is Zimmer (ZBH) Up 10.8% Since Last Earnings Report?

Investors are optimistic about Zimmer Biomet (ZBH), driven by a recovery in business and an expanding global footprint.

Here's Why You Should Retain Zimmer Biomet (ZBH) for Now

Zimmer Biomet has seen a strong operating performance despite years of stagnation, making its shares compelling. The company's valuation has become more reasonable, with revenues trending at around $7.3 billion and adjusted earnings reported at $7.50 per share. The impact of GLP-1 drugs on demand for Zimmer Biomet's products raises concerns about future growth.

Zimmer Biomet: Still Many Questions After A Solid Year So Far

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Why Zimmer Biomet (ZBH) is a Top Momentum Stock for the Long-Term

Zimmer Biomet (ZBH) is working to strengthen its foothold in emerging markets that provide long-term opportunities for growth.

Zimmer Biomet's (ZBH) Knee Sales Robust, Macro Woes Hurt

WARSAW, Ind. , Nov. 16, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced that members of the Zimmer Biomet management team will be presenting at the 2023 Piper Sandler Healthcare Conference on Thursday, November 30, 2023, at 9:00 a.m.

Zimmer Biomet to Present at the 2023 Piper Sandler Healthcare Conference

Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q3 2023 Earnings Conference Call November 7, 2023 8:30 AM ET Company Participants Keri Mattox – Chief Communications and Administration Officer Ivan Tornos – President and Chief Executive Officer Suky Upadhyay – Executive Vice President and Chief Financial Officer Conference Call Participants Robbie Marcus – JPMorgan Drew Ranieri – Morgan Stanley Matt Taylor – Jefferies Shagun Singh – RBC Capital Markets Josh Jennings – TD Cowen Larry Biegelsen – Wells Fargo Chris Pasquale – Nephron Travis Steed – Bank of America Vijay Kumar – Evercore ISI Operator Good morning, ladies and gentlemen, and welcome to the Zimmer Biomet's Third Quarter 2023 Earnings Conference Call. [Operator Instructions] As a reminder, this conference is being recorded today November 7.

Zimmer Biomet Holdings, Inc. (ZBH) Q3 2023 Earnings Call Transcript

Zimmer Biomet (ZBH) gains from solid strategic execution and increasing traction in innovations in the third quarter.

Zimmer Biomet (ZBH) Q3 Earnings Top Estimates, Margins Fall

The headline numbers for Zimmer (ZBH) give insight into how the company performed in the quarter ended September 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Zimmer (ZBH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

Zimmer Biomet (ZBH) came out with quarterly earnings of $1.65 per share, beating the Zacks Consensus Estimate of $1.59 per share. This compares to earnings of $1.58 per share a year ago.

Zimmer Biomet (ZBH) Q3 Earnings and Revenues Top Estimates

Zimmer Biomet Holdings Inc on Tuesday beat Wall Street estimates for third-quarter profit, as a rebound in knee surgeries lifted demand for the medical device maker's products.

Zimmer Biomet beats quarterly profit estimates on knee procedure strength

Third quarter net sales of $1.754 billion increased 5.0% and 4.7% on a constant currency1 basis Third quarter diluted earnings per share were $0.77; adjusted1 diluted earnings per share were $1.65 The Company updates 2023 reported revenue guidance due to currency expectations and reaffirms 2023 constant currency revenue growth and adjusted1 earnings per share financial guidance WARSAW, Ind. , Nov. 7, 2023 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today reported financial results for the quarter ended September 30, 2023.

Zimmer Biomet Announces Third Quarter 2023 Financial Results

Zimmer Biomet (ZBH) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Zimmer Biomet (ZBH) Might Surprise This Earnings Season

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Zimmer (ZBH), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2023.

Stay Ahead of the Game With Zimmer (ZBH) Q3 Earnings: Wall Street's Insights on Key Metrics

Zimmer Biomet (ZBH) is expected to have witnessed strong performance across Avenir Complete hip.

News for Zimmer Biomet Hlds Stock (ZBH)